Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Akero Therapeutics Inc | AKRO | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 21.02 | 04:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 21.02 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 11.25 - 58.38 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 21.02 | USD |
Akero Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 1.18B | 56.30M | - | 0 | -151.76M | -2.70 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Akero Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AKRO Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 20.44 | 22.26 | 19.63 | 21.08 | 592,542 | 0.58 | 2.84% |
| 1 Month | 22.15 | 22.42 | 18.20 | 20.81 | 711,243 | -1.13 | -5.10% |
| 3 Months | 21.65 | 37.00 | 18.20 | 26.17 | 1,303,065 | -0.63 | -2.91% |
| 6 Months | 15.29 | 37.00 | 13.3888 | 23.21 | 1,189,870 | 5.73 | 37.48% |
| 1 Year | 45.18 | 58.38 | 11.25 | 27.65 | 1,217,614 | -24.16 | -53.47% |
| 3 Years | 27.15 | 58.38 | 7.52 | 29.03 | 744,781 | -6.13 | -22.58% |
| 5 Years | 16.16 | 58.38 | 7.52 | 28.78 | 536,799 | 4.86 | 30.07% |
Akero Therapeutics Description
| Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis. |
